Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FOLD Amicus Therapeutics	$7.95 -2.6%	$9.22	$7.90 ▼ $12.65	$2.44B	0.69	2.53 million shs	2.98 million shs
MBX MBX Biosciences	$6.86 -7.0%	$9.77	$6.77 ▼ $27.50	$229.29M	N/A	231,852 shs	197,317 shs
MRUS Merus	$39.60 -5.9%	$44.03	$37.77 ▼ $61.61	$2.74B	1.15	697,201 shs	1.76 million shs
XENE Xenon Pharmaceuticals	$30.64 -8.7%	$37.45	$30.58 ▼ $46.00	$2.35B	1.26	398,467 shs	1.12 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FOLD Amicus Therapeutics	-2.57%	-7.77%	-16.23%	-15.61%	-32.34%
MBX MBX Biosciences	-7.05%	-11.94%	-28.54%	-62.78%	+685,999,900.00%
MRUS Merus	-5.92%	-15.71%	-15.91%	-5.83%	-12.08%
XENE Xenon Pharmaceuticals	-8.67%	-12.21%	-17.23%	-21.84%	-27.29%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FOLD Amicus Therapeutics	4.0578 of 5 stars	3.4	1.0	4.3	2.5	0.8	1.9
MBX MBX Biosciences	1.9553 of 5 stars	3.5	0.0	0.0	1.6	1.7	0.6
MRUS Merus	2.1722 of 5 stars	4.6	0.0	0.0	2.2	1.7	0.0
XENE Xenon Pharmaceuticals	2.4295 of 5 stars	3.5	2.0	0.0	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FOLD Amicus Therapeutics	2.78	Moderate Buy	$16.75	110.69% Upside
MBX MBX Biosciences	3.00	Buy	$37.25	443.00% Upside
MRUS Merus	3.13	Buy	$85.31	115.42% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$57.38	87.26% Upside

Current Analyst Ratings Breakdown

Latest MBX, XENE, MRUS, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	MRUS Merus	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$109.00 ➝ $109.00
3/18/2025	MRUS Merus	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$109.00 ➝ $109.00
3/10/2025	MRUS Merus	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
3/3/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $85.00
2/28/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
2/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/28/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$85.00 ➝ $83.00
2/28/2025	XENE Xenon Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/24/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
2/20/2025	FOLD Amicus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $17.00
2/20/2025	FOLD Amicus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FOLD Amicus Therapeutics	$528.30M	4.62	N/A	N/A	$0.63 per share	12.62
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	$36.13M	75.72	N/A	N/A	$6.17 per share	6.42
XENE Xenon Pharmaceuticals	$9.43M	248.70	N/A	N/A	$14.18 per share	2.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FOLD Amicus Therapeutics	-$151.58M	-$0.18	N/A	18.49	1.51	-10.62%	12.44%	2.60%	5/8/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	-$154.94M	-$3.27	N/A	N/A	N/A	-680.61%	-38.89%	-31.16%	5/6/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.02	N/A	N/A	N/A	N/A	-24.69%	-23.68%	5/8/2025 (Estimated)

Latest MBX, XENE, MRUS, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/27/2025	Q4 2024	MRUS Merus	-$0.89	-$0.41	+$0.48	-$0.41	$10.57 million	$9.14 million
2/27/2025	Q4 2024	XENE Xenon Pharmaceuticals	-$0.89	-$0.84	+$0.05	-$0.84	$0.31 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FOLD Amicus Therapeutics	2.01	3.39	2.42
MBX MBX Biosciences	N/A	N/A	N/A
MRUS Merus	N/A	8.32	8.32
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FOLD Amicus Therapeutics	N/A
MBX MBX Biosciences	N/A
MRUS Merus	96.14%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
FOLD Amicus Therapeutics	2.20%
MBX MBX Biosciences	N/A
MRUS Merus	4.57%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FOLD Amicus Therapeutics	480	307.24 million	292.23 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
MRUS Merus	37	69.09 million	65.34 million	Optionable
XENE Xenon Pharmaceuticals	210	76.54 million	72.03 million	Optionable

MBX, XENE, MRUS, and FOLD Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Analysts

April 2 at 2:30 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week Low - Time to Sell?

April 1 at 12:22 PM | marketbeat.com

DnB Asset Management AS Purchases 12,620 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 31 at 5:02 AM | marketbeat.com

Pictet Asset Management Holding SA Reduces Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 31 at 4:54 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded to Hold at StockNews.com

March 30 at 3:19 AM | americanbankingnews.com

StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold

March 30 at 2:16 AM | marketbeat.com

Loomis Sayles & Co. L P Sells 20,077 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 29, 2025 | marketbeat.com

BIT Capital GmbH Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 28, 2025 | marketbeat.com

Fox Run Management L.L.C. Has $338,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 27, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - Here's Why

March 26, 2025 | marketbeat.com

What is William Blair's Forecast for XENE Q1 Earnings?

March 20, 2025 | marketbeat.com

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

March 20, 2025 | marketbeat.com

Xenon to Present at Stifel 2025 Virtual CNS Forum

March 12, 2025 | financialpost.com

Xenon to Present at Stifel 2025 Virtual CNS Forum

March 12, 2025 | globenewswire.com

FMR LLC's Strategic Acquisition of Xenon Pharmaceuticals Inc. Shares

March 7, 2025 | gurufocus.com

Candriam S.C.A. Purchases 28,320 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

March 7, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages

March 7, 2025 | marketbeat.com

Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

March 6, 2025 | marketbeat.com

FY2028 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

March 3, 2025 | marketbeat.com

Q1 Earnings Forecast for XENE Issued By HC Wainwright

March 3, 2025 | marketbeat.com

Equities Analysts Offer Predictions for XENE Q1 Earnings

March 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX, XENE, MRUS, and FOLD Company Descriptions

Amicus Therapeutics NASDAQ:FOLD

$7.95 -0.21 (-2.57%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$7.88 -0.08 (-0.94%)

As of 04/1/2025 05:08 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

MBX Biosciences NYSE:MBX

$6.86 -0.52 (-7.05%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$6.86 0.00 (-0.07%)

As of 04/1/2025 04:38 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Merus NASDAQ:MRUS

$39.60 -2.49 (-5.92%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$39.62 +0.02 (+0.04%)

As of 04/1/2025 06:34 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Xenon Pharmaceuticals NASDAQ:XENE

$30.64 -2.91 (-8.67%)

Closing price 04/1/2025 04:00 PM Eastern

Extended Trading

$32.86 +2.22 (+7.26%)

As of 04/1/2025 07:54 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time